Clinical Trial

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Study acronym: ERADICATE
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the safety and efficacy of elacestrant in combination with trastuzumab deruxtecan (T-DXd) in participants with hormone receptor-positive (HR+), HER2-low or HER2-ultralow, metastatic breast cancer that is resistant to prior CDK4/6 inhibitor and endocrine therapy. The names of the study drugs involved in this study are: * Elacestrant (a type of selective estrogen receptor degrader) * Trastuzumab deruxtecan (a type of standard of care antibody drug conjugate)
Protocol Amendment History 1 change
notable Sponsor changed: Sarah Sammons, MD -> Kristina A. Fanucci 2026-06-11
Trial Details
NCT Number NCT07198724
Lead Sponsor Kristina A. Fanucci
Collaborators: Stemline Therapeutics, Inc.
Conditions Metastatic Breast Cancer, HER2 Low Breast Carcinoma, HER2-negative Breast Cancer, Breast Cancer, Breast Cancer Female
Enrollment 65 participants
Start Date 2025-11-17
Primary Completion 2028-06-01 (estimated)
Study Completion 2038-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-10